Thermogenesis and fructose metabolism in humans.
Resting metabolic rate was measured in 10 healthy volunteers (25 yr, 73 kg, 182 cm) for 1 h before and 4 h during intravenous (iv) fructose administration (20% at 50 mumol.kg-1.min-1) with (+P) or without (-P) propranolol (100 micrograms/kg, 1 microgram.kg-1.min-1) during the last 2 h. Some subjects were studied a further 2 h with fructose infusion and +P or -P in hyperinsulinemic (2.9 pmol.kg-1.min-1) euglycemic conditions. Glucose turnover ([3-3H]glucose, 20 muCi bolus and 0.2 muCi/min) was calculated over 30 min at 0, 2, 4, and 6 h. The thermic effect of iv fructose was approximately 7.5% and decreased to 4.9 +/- 0.4% (P less than 0.01) +P. During the euglycemic clamp the thermic effect was 6.2 +/- 0.9% (-P) and 5.3 +/- 0.9% (+P). Hepatic glucose production (HGP) was 11.7 mumol.kg-1.min-1 (0 h) and did not change after 2 h iv fructose (11.8 +/- 0.5 and 9.8 +/- 0.6 mumol.kg-1.min-1 -P and +P, respectively) but increased to 13.8 +/- 0.9 (-P) and 12.9 +/- 0.8 mumol.kg-1.min-1 (+P) (P less than 0.01) after 4 h. HGP was suppressed to varying degrees during the euglycemic clamp. It is concluded that 1) the greater thermic effect of fructose compared with glucose is probably due to continued gluconeogenesis (which is suppressed by glucose or glucose-insulin) and the energy cost of fructose metabolism to glucose in the liver. 2) There is a sympathetically mediated component to the thermic effect of fructose (approximately 30%) that is not mediated by elevated plasma insulin concentrations similar to those observed with iv glucose.
Schwarz
J M
JM
Institute of Physiology, Lausanne University Medical School, Switzerland.
Acheson
K J
KJ
Tappy
L
L
Piolino
V
V
Müller
M J
MJ
Felber
J P
JP
Jéquier
E
E
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D001831:Body Temperature / Q000187:drug effects; D001833:Body Temperature Regulation; D050260:Carbohydrate Metabolism; D005632:Fructose / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D006339:Heart Rate; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D011659:Pulmonary Gas Exchange
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D007328:Insulin; D005632:Fructose; D011433:Propranolol; D005947:Glucose